Hypopharynx

Changes from the AJCC 7th Edition
  • Mostly unchanged from the 7th Edition.
  • T0 has been removed as a category
  • T3 criteria have been changed from "extension to esophagus" to "extension to esophageal mucosa." T4a criteria now includes invasion of esophageal muscle.
  • This staging system now uses the new shared nodal and group staging described previously.

T-Categorization
T Category Criteria
TX

Primary tumour cannot be assessed

Tis

Carcinoma in situ.

T1

2 cm or smaller in greatest dimension AND involving 1 subsite of the hypopharynx only.

T2
  • >2 cm - 4 cm in greatest dimension.
  • OR involvement of more than 1 subsite of the hypopharynx.
T3
  • > 4 cm in greatest dimension.
  • OR fixation of the hemilarynx.
  • OR extension to the mucosa of the esophagus.
T4 Moderately advanced (T4a) or very advanced (T4b) disease
T4a
  • Moderately advanced local disease
  • Tumour invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, esophageal muscle or central compartment soft tissue.
  • Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.
T4b
  • Very advanced local disease
  • Tumour invasion of the prevertebral fascia, carotid artery encasement, or involves mediastinal structures.

General Rules

  • Subsites of the Hypopharynx include (the 3 P's):
    1. PPyriform sinuses
    2. PPosterior pharyngeal wall
    3. PPost-cricoid space
  • To be categorized as T1 a tumour has to be ≤2 cm and involving 1 subsite of the hypopharynx only.
  • To be categorized as T2 a tumour has to be either >2 - 4 cm or involving 2 or more subsites of the hypopharynx.
  • Similar to in the larynx, vocal fold fixation (fixation of the hemilarynx) upcategorizes to T3
  • Involvement of the esophageal mucosa upcategorizes to T3, while involvement of the esophageal muscle upcategorizes to T4a
  • T4a is also defined by extension essentially to any of the structures in the central neck (thyroid gland, cricoid/thyroid/hyoid, straps, or central compartment fat).

N-Categorization

Clinical Nodal Categorization
(Shared Categorization System)

N Category Criteria
NX

Regional lymph nodes cannot be assessed.

N0

No regional lymph node metastasis.

N1
  • Single ipsilateral lymph node that is 3 cm or less in maximal dimension without extranodal extension
N2
N2a
  • Single ipsilateral lymph node that is > 3 cm but ≤ 6 cm in maximal dimension without extranodal extension
N2b
  • Mulple ipsilateral lymph nodes that are ≤ 6 cm in maximal dimension without extranodal extension
N2c
  • Bilateral or contralateral lymph nodes that are ≤ 6 cm in maximal dimension without extranodal extension
N3
N3a

Metastasis in any lymph node > 6 cm without extranodal extension

N3b

Metastasis in any lymph node with clinically overt extranodal extension.

Pathologic Nodal Categorization
(Shared Categorization System)

N Category Criteria
NX

Regional lymph nodes cannot be assessed.

N0

No regional lymph node metastasis.

N1
  • Single ipsilateral lymph node that is 3 cm or less in maximal dimension without extranodal extension
N2
N2a
  • Single ipsilateral lymph node that is > 3 cm but ≤ 6 cm in maximal dimension without extranodal extension
  • OR metastasis to a single ipsilateral lymph node that is 3 cm or less in maximal dimension WITH extranodal extension
N2b
  • Mulple ipsilateral lymph nodes that are ≤ 6 cm in maximal dimension without extranodal extension
N2c
  • Bilateral or contralateral lymph nodes that are ≤ 6 cm in maximal dimension without extranodal extension
N3
N3a

Metastasis in any lymph node > 6 cm without extranodal extension

N3b
  • Metastasis in any lymph node with clinically overt extranodal extension.
  • EXCEPT if it a single ipsilateral node that is 3 cm or less with extranodal (which would instead be categorized as N2a as above).

General Rules

  • Uses the Shared Nodal Staging System described previously.
  • If a patient has any clinical extranodal extension, they are automatically be categorized in the maximum possible N sub-category (N3b).
  • Pathologic N categorization is almost the same except for the isolated situation of having a single ipsilateral lymph node that is 3 cm or less with ENE identified only on pathology.
    • Instead of being up-categorized to N3b, this specific case is up-categorized to N2a instead.
    • In all other situations where there is ENE (clinical or pathologic), they are still up-categorized to N3b.
  • Clinically the AJCC defines ENE as invasion of skin, infiltration of musculature/fixation to adjacent structures on clinical examination, cranial nerve, brachial plexus, sympathetic trunk or phrenic nerve invasion with dysfunction.

Extranodal Extension (ENE)

  • Pathologically, ENE is defined as extension of metastatic tumour beyond the confines of the lymph node itself.
  • Clinically the AJCC defines ENE as invasion of skin, infiltration of musculature/fixation to adjacent structures on clinical examination, cranial nerve, brachial plexus, sympathetic trunk or phrenic nerve invasion with dysfunction.

M-Categorization
M Category Criteria
M0

No distant metastasis

M1

Distant metastasis present


Group Staging

Shared Group Staging System

N0
M0
N1
M0
N2
M0
N3
M0
Any N
M1
T1 I III IVA IVB IVC
T2 II III IVA IVB IVC
T3 III III IVA IVB IVC
T4a IVA IVA IVA IVB IVC
T4b IVB IVB IVB IVB IVC

General Rules

  • Uses the Shared Group Staging System described previously.
  • Straightforward to remember due to the pattern seen above when creating a table against the T and N staging.
  • (T1 N0) is staged as Stage I, and (T2, N0) is staged as Stage II. Thereafter, each increasing stage is immediately to the right and below the previous stage.